Skip to main content
. 2022 Oct 31;19(13):1977–1988. doi: 10.7150/ijms.77193

Table 2.

Association of high PD-L1 expression with the clinicopathological characteristics of 91 patients with retroperitoneal liposarcoma

Characteristics Total High PD-L1 expression (%) Low PD-L1 expression (%) P value
Gender
Male 52 4(7.7) 48(92.3) >0.999
Female 39 3(7.7) 36(92.3)
Age
≤60 55 4(7.3) 51(92.7) >0.999
>60 36 3(8.3) 33(91.7)
Tumor size
≤15 16 2(12.5) 14(87.5) 0.051
15-30 50 1(2.0) 49(98.0)
>30 25 4(16.0) 21(84.0)
FNCLCC Grade
Low (G1) 20 3(15.0) 17(85.0) 0.361
High (G2, G3) 71 4(5.6) 67(94.4)
Histology
DDLPS 61 5(8.2) 56(91.8) 0.270
WDLPS 21 1(4.8) 20(95.2)
PLPS 7 0(0) 7(100)
MLPS 2 1(50.0) 1(50.0)
Multifocality
No 54 3(5.5) 51(94.4) 0.436
Yes 37 4(10.8) 33(89.2)
Recurrence
No 38 1(2.1) 47(97.9) 0.049
Yes 43 6(14.0) 37(86.0)
Necrosis
No 60 5(8.3) 55(91.7) >0.999
Yes 31 2(6.5) 29(93.5)

Abbreviations: SD, standard deviation; FNCLCC, Federation Nationale des Centres de Lutte Contre le Cancer; PD-L1, programmed death ligand 1; WDLPS, well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; PLPS, pleomorphic liposarcoma; MLPS, myxoid/round cell liposarcoma.